French drugmaker Sanofi SA is partnering with British AI firm Exscientia Plc to develop up to 15 drug candidates across oncology and immunology, in a deal worth up to $5.2 billion in milestone payments, the two companies said on January 7.

San Francisco-based biotech company Alumis, formerly Esker Therapeutics, closed on a $200 million Series B financing round.

The share price of Arena Pharmaceuticals nearly doubled in premarket trading after pharma giant Pfizer announced the acquisition of the company and its diverse portfolio of developmental and clinical assets – including a late-stage ulcerative colitis treatment – in an all-cash deal valued at $6.7 billion.

AstraZeneca said on Nov. 1 the company will transfer global rights for respiratory medicines Eklira and Duaklir to Covis Pharma Group for $270 million, as the Anglo-Swedish drugmaker looks to offload its older portfolio of medicines.

Immunology is one of the more complicated areas of the life sciences, and recent studies on the long-term efficacy of the mRNA vaccines against Covid-19 are prime examples of just how complicated it can be.

Eli Lilly is undertaking a strategic transformation that will result in the formation of new business units. The Indianapolis company’s Bio-Medicines unit will split into two separate businesses, with one focused on neuroscience and the other concentrated on immunology.

Shares of Autolus Therapeutics were up in trading after the company announced an exclusive licensing agreement with Moderna to develop new messenger RNA therapeutics for cancer.

AbbVie’s Rinvoq continues to demonstrate the medicine’s clinical potential to become the heir-apparent to the company’s blockbuster drug Humira, which will lose patent protection in 2023. In the company’s second-quarter 2021 report, AbbVie touted advances Rinvoq made throughout the three months, including positive Phase III data in ulcerative colitis.

Venture capitalist Chamath Palihapitiya is raising $800 million to finance four more special purpose acquisition companies (SPAC) that will be focused on taking biotech companies public.

During the Digestive Disease Week meeting, AbbVie presented late-breaking data analyses that showed both doses of Skyrizi met the co-primary endpoints of clinical remission and endoscopic response at week 12 compared to placebo in two Phase III studies. The Lancet published results from pivotal global Phase III clinical trials – Measure Up 1, Measure Up 2 and AD Up – evaluating Rinvoq (upadacitinib) in adults and adolescents with mild to severe atopic dermatitis who were candidates for systemic treatment.